United Therapeutics CorporationUTHRNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank49
Year-over-Year Change
Year-over-year operating income growth rate
Latest
-8.19%
↓ 224% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
6.62%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -8.19% |
| Q3 2025 | 6.58% |
| Q2 2025 | -4.78% |
| Q1 2025 | 7.02% |
| Q4 2024 | 4.26% |
| Q3 2024 | 7.25% |
| Q2 2024 | -10.22% |
| Q1 2024 | 36.99% |
| Q4 2023 | -20.46% |
| Q3 2023 | 4.34% |
| Q2 2023 | 10.20% |
| Q1 2023 | 61.96% |
| Q4 2022 | -44.13% |
| Q3 2022 | 55.75% |
| Q2 2022 | -29.93% |
| Q1 2022 | 69.61% |
| Q4 2021 | -25.75% |
| Q3 2021 | 2.93% |
| Q2 2021 | 442.90% |
| Q1 2021 | -199.23% |
| Q4 2020 | -70.47% |
| Q3 2020 | 57.37% |
| Q2 2020 | -15.72% |
| Q1 2020 | 162.52% |
| Q4 2019 | -65.38% |
| Q3 2019 | -17.16% |
| Q2 2019 | 133.76% |
| Q1 2019 | -598.78% |
| Q4 2018 | -12.10% |
| Q3 2018 | -31.19% |
| Q2 2018 | -29.16% |
| Q1 2018 | 120.79% |
| Q4 2017 | -57.07% |
| Q3 2017 | 265.88% |
| Q2 2017 | -66.43% |
| Q1 2017 | 51.32% |
| Q4 2016 | -26.99% |
| Q3 2016 | -16.34% |
| Q2 2016 | -21.58% |
| Q1 2016 | 134.56% |